PLANTATION, Fla., Nov. 21 /PRNewswire-FirstCall/ -- Representatives from
Viragen, Inc. (Amex: VRA) and Viragen International, Inc.
(OTC Bulletin Board: VGNI) provided comments related to a recent announcement
reporting positive preliminary in vitro results from studies on Multiferon(R)
(multi-subtype, human natural alpha interferon) and the H5N1 virus, the cause
of avian flu.
President and CEO Charles A. Rice expressed cautious optimism stating,
"While the initial results obtained by Southern Research Institute are
encouraging, they do strongly suggest the need for further studies to
determine how Multiferon(R) might be used in combating the avian influenza
threat. It is widely publicized that some drugs currently being stockpiled
could be susceptible to viral resistance, or may not be active against this
particular strain of the virus. Additionally, the virus responsible for any
eventual pandemic may not be the H5N1 strain. Multiferon(R) may represent a
different approach to treatment in that it has been shown to exhibit rather
broad anti-viral activity. I can also confirm that separate studies are
ongoing in a variety of other emerging viral threats in cooperation with a
number of independent investigators."
Vice President and Managing Director of Viragen (Scotland) Ltd. Karen
Jervis, Ph.D., outlined the steps necessary to position the product as an
avian flu treatment candidate, "We need to conduct further confirmatory in
vitro investigations to determine the lower ranges at which Multiferon(R) is
active against the virus, while directly comparing it to a broader spectrum of
anti-viral products. Provided these results are supportive, we would then
want to progress to in vivo studies to assess the activity. We are currently
investigating availability of grants, government funding opportunities,
government and institutional research collaborations and all other means
whereby we can complete additional work."
About Multiferon(R):
Multiferon(R) is a highly purified, multi-subtype, natural human alpha
interferon. Marketed as "the natural choice"(TM), it is approved for sale in
ten international markets (non-U.S.) for the first-line or rescue therapy of a
broad range of infectious diseases and cancers. Earlier this year, Viragen
filed an application in Sweden to seek expanded approval for Multiferon(R) to
include the first-line adjuvant treatment of high-risk malignant melanoma. A
decision is expected imminently.
About Viragen, Inc.:
With global operations in the U.S., Scotland and Sweden, Viragen is a
biotechnology company engaged in the research, development, manufacture and
commercialization of pharmaceutical proteins for the treatment of viral
diseases and cancers. Our product portfolio includes: Multiferon(R) (multi-
subtype, natural human alpha interferon) targeting a broad range of infectious
and malignant diseases; and humanized monoclonal antibodies targeting specific
antigens over-expressed on many types of cancers. We are also pioneering the
development of Avian Transgenic Technology, with the renowned Roslin
Institute, as a revolutionary manufacturing platform for the large-scale,
efficient and economical production of human therapeutic proteins and
antibodies.
For more information, please visit: http://www.Viragen.com .
Viragen, Inc. Corporate Contact:
Douglas Calder, Director of Communications
Phone: (954) 233-8746; Fax: (954) 233-1414
E-mail: dcalder@viragen.com
The foregoing press announcement contains forward-looking statements that
can be identified by terminology such as "expect," "potential," "suggests,"
"may," "should," "could" or similar expressions. Such forward-looking
statements involve known and unknown risks, uncertainties and other factors
that may cause the actual results to be materially different from any future
results, performance or achievements expressed or implied by such statements.
In particular, management's expectations regarding future research,
development and/or commercial results could be affected by, among other
things, uncertainties relating to clinical trials and product development;
availability of future financing; unexpected regulatory delays or government
regulation generally; the Company's ability to obtain or maintain patent and
other proprietary intellectual property protection; and competition in
general. Forward-looking statements speak only as to the date they are made.
The Company does not undertake to update forward-looking statements to reflect
circumstances or events that occur after the date the forward-looking
statements are made.
SOURCE Viragen, Inc.
 back to top
Related links:
http://www.viragen.com
Photo Notes:
NewsCom:
http://www.newscom.com/cgi-bin/prnh/20010426/HSTH018LOGO-b
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, photodesk@prnewswire.com
CONTACT:
Douglas Calder, Director of Communications,
Viragen, +1-954-233-8746, or fax, +1-954-233-1414, or
dcalder@viragen.com
|
